Larimar Therapeutics, Inc. (Nasdaq:LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.
Location: United States, Pennsylvania, Lower Merion Township
Employees: 11-50
Founded date: 2016
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Mentions in press and media 22
| Date | Title | Description | Source |
| 11.03.2024 | Larimar Therapeutics Announces the Dosing of the First Patie... | - | globenewsw... |
| 06.03.2024 | Larimar Therapeutics to Present at the Leerink Partners Glob... | - | globenewsw... |
| 11.08.2022 | Larimar Therapeutics Provides Updates on CTI-1601 Clinical P... | Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022... | globenewsw... |
| 19.05.2022 | Larimar Therapeutics Announces Upcoming Poster Presentations... | BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: L... | globenewsw... |
| 12.05.2022 | Larimar Therapeutics Reports First Quarter 2022 Operating an... | - CTI-1601 Type C Meeting to discuss clinical hold has been granted by the U.S. Food and Drug Admini... | globenewsw... |
| 25.03.2022 | Larimar Therapeutics Reports Fourth Quarter and Full Year 20... | BALA CYNWYD, Pa., March 25, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq:... | globenewsw... |
| 15.02.2022 | Larimar Therapeutics : Provides Update on CTI-1601 Clinical ... | Larimar Therapeutics Provides Update on CTI-1601 Clinical Program Bala Cynwyd, PA, February 14, 2022... | marketscre... |
| 15.02.2022 | Larimar Therapeutics Provides Update on CTI-1601 Clinical Pr... | BALA CYNWYD, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: ... | marketscre... |
| 12.11.2021 | Larimar Therapeutics Reports Third Quarter 2021 Operating an... | BALA CYNWYD, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: ... | globenewsw... |
| 12.11.2021 | Larimar Therapeutics Reports Third Quarter 2021 Operating an... | Larimar Therapeutics Reports Third Quarter 2021 Operating and Financial Results Bala Cynwyd, PA, Nov... | marketscre... |
Show more